Update shared on09 Oct 2025
Fair value Decreased 5.65%Evonik Industries’ analyst price target has been reduced from €19.88 to €18.75 as analysts cite increased downside risks to earnings from both cyclical and structural factors.
Analyst Commentary
Recent analyst activity reflects a mixed outlook on Evonik Industries, with both optimistic and cautious perspectives shaping the current consensus on the stock's valuation and prospects.
Bullish Takeaways
- Bullish analysts have maintained an Overweight rating, which signals continued confidence in Evonik’s relative performance compared to the broader market.
- Despite lowering price targets, some see fundamental strengths supporting Evonik’s valuation near current levels.
- Stable long-term demand in core business segments is cited as a reason for optimism regarding future growth potential.
- Recent adjustments in price targets are seen by some as aligning more closely with current earnings visibility rather than indicating structural weaknesses.
Bearish Takeaways
- Bearish analysts point to intensified downside risks to earnings due to ongoing cyclical and structural industry pressures.
- Several price targets have been lowered in recent research, reflecting increased caution about execution and macroeconomic challenges.
- Concerns persist about Evonik’s ability to achieve previous profitability targets in a more volatile environment.
- There is skepticism that additional downgrades may occur if market conditions or the sector outlook weaken.
What's in the News
- Evonik Industries provided earnings guidance for the third quarter of 2025, anticipating revenue of around €3.4 billion, which is down from €3.8 billion in the third quarter of 2024 (Key Developments).
- Evonik and Ethris announced a strategic collaboration to develop and market a novel lipid nanoparticle (LNP) platform for nucleic acid delivery. This partnership aims to enhance the stability and targeting of nucleic acid therapies and vaccines (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has fallen by approximately €1.13, from €19.88 to €18.75.
- Discount Rate has risen slightly, from 6.28% to 6.33%.
- Revenue Growth projection has fallen significantly, decreasing from 0.89% to 0.37%.
- Net Profit Margin has edged down modestly, from 4.82% to 4.71%.
- Future P/E ratio estimate has declined from 14.81x to 14.54x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.